Henan Newland Pharmaceutical Co. Ltd. A - Asset Resilience Ratio

Latest as of March 2026: 29.76%

Henan Newland Pharmaceutical Co. Ltd. A (301277) has an Asset Resilience Ratio of 29.76% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Henan Newland Pharmaceutical Co. Ltd. A free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.

Liquid Assets

CN¥542.35 Million
≈ $79.36 Million USD Cash + Short-term Investments

Total Assets

CN¥1.82 Billion
≈ $266.71 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Henan Newland Pharmaceutical Co. Ltd. A's Asset Resilience Ratio has changed over time. See how leveraged is Henan Newland Pharmaceutical Co. Ltd. A's balance sheet to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Henan Newland Pharmaceutical Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 301277 market cap.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥542.35 Million 29.76%
Total Liquid Assets CN¥542.35 Million 29.76%

Asset Resilience Insights

  • Very High Liquidity: Henan Newland Pharmaceutical Co. Ltd. A maintains exceptional liquid asset reserves at 29.76% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Henan Newland Pharmaceutical Co. Ltd. A Industry Peers by Asset Resilience Ratio

Compare Henan Newland Pharmaceutical Co. Ltd. A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
SIMCERE PHARMAC. GRP LTD
F:S2P
Drug Manufacturers - Specialty & Generic 0.44%
Curaleaf Holdings Inc.
TO:CURA
Drug Manufacturers - Specialty & Generic 3.73%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Walvax BioTech
SHE:300142
Drug Manufacturers - Specialty & Generic 2.20%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%

Annual Asset Resilience Ratio for Henan Newland Pharmaceutical Co. Ltd. A (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Henan Newland Pharmaceutical Co. Ltd. A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 30.88% CN¥549.55 Million
≈ $80.42 Million
CN¥1.78 Billion
≈ $260.40 Million
+1.93pp
2024-12-31 28.95% CN¥525.16 Million
≈ $76.85 Million
CN¥1.81 Billion
≈ $265.41 Million
-7.67pp
2023-12-31 36.63% CN¥589.50 Million
≈ $86.26 Million
CN¥1.61 Billion
≈ $235.52 Million
-9.10pp
2022-12-31 45.73% CN¥701.36 Million
≈ $102.63 Million
CN¥1.53 Billion
≈ $224.44 Million
+44.43pp
2021-12-31 1.30% CN¥8.67 Million
≈ $1.27 Million
CN¥667.90 Million
≈ $97.74 Million
--
pp = percentage points

About Henan Newland Pharmaceutical Co. Ltd. A

SHE:301277 China Drug Manufacturers - Specialty & Generic
Market Cap
$516.36 Million
CN¥3.53 Billion CNY
Market Cap Rank
#12216 Global
#3555 in China
Share Price
CN¥9.00
Change (1 day)
+0.33%
52-Week Range
CN¥8.97 - CN¥16.34
All Time High
CN¥19.48
About

Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naph… Read more